Overview

CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Single-center, interventional, open-label, randomized phase II study aimed at describing the changes in airway inflammation at the onset of asthma symptoms that lead to the use of rapid acting bronchodilator (RABD) as a rescue medication in a mild to moderate asthma population. The study will assess whether there are differences in the airway inflammation profile in patients using a reliever medication containing ICS (anti-inflammatory rescue strategy) compared to a reliever medication containing only a bronchodilator for symptom relief (Non anti-inflammatory rescue strategy).
Phase:
PHASE2
Details
Lead Sponsor:
Università degli Studi di Ferrara
Treatments:
Albuterol
Beclomethasone
Budesonide